文献速递泌尿男性生殖肿瘤头颈与中枢神经肿瘤

肿瘤放射诊疗一体化:使精准医学成为可能

Radiotheranostics in oncology: Making precision medicine possible.
PubMed 文献 · CA Cancer J Clin · 2023-01-09

放射诊疗一体化利用与诊断相同或相似的工具,对显像阳性的患者进行治疗,以实现高治疗指数。该领域在肿瘤学中快速发展,针对前列腺癌PSMA和神经内分泌肿瘤SSTR2的放射诊疗一体化正成为常规,部分大转移负荷患者可出现完全或部分缓解,但并非所有患者获益。

要点

  • 放射诊疗一体化采用与诊断相同或相似的工具,仅治疗显像阳性的患者。
  • 在表达PSMA的前列腺癌和表达SSTR2的神经内分泌肿瘤患者中,放射诊疗一体化正成为常规。
  • 部分大转移负荷患者可出现完全和部分缓解,但并非所有患者均获益。

核心结论

  • 放射诊疗一体化在肿瘤学中快速发展,针对表达PSMA的前列腺癌和表达SSTR2的神经内分泌肿瘤已成为常规,部分大转移负荷患者可出现完全和部分缓解。
  • 并非所有患者均能从放射诊疗一体化中获益,但对达到靶点检测阳性的患者,缓解可能性非常高。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 放射诊疗一体化利用放射性药物,在表达PSMA的前列腺癌和表达SSTR2的神经内分泌肿瘤患者中正成为常规。
  • 部分大转移负荷患者出现完全和部分缓解,这一结果正在推动更多放射诊疗一体化方法的探索。
  • 并非所有患者均获益,但对达到靶点检测阳性的患者,缓解可能性非常高。

关键数值与推荐

  • 原文未报告具体标准与数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A quintessential setting for precision medicine, theranostics refers to a rapidly evolving field of medicine in which disease is diagnosed followed by treatment of disease-positive patients using tools for the therapy identical or similar to those used for the diagnosis. Against the backdrop of only-treat-when-visualized, the goal is a high therapeutic index with efficacy markedly surpassing toxicity. Oncology leads the way in theranostics innovation, where the approach has become possible with the identification of unique proteins and other factors selectively expressed in cancer versus healthy tissue, advances in imaging technology able to report these tissue factors, and major understanding of targeting chemicals and nanodevices together with methods to attach labels or warheads for imaging and therapy. Radiotheranostics-using radiopharmaceuticals-is becoming routine in patients with prostate cancer and neuroendocrine tumors who express the proteins PSMA (prostate-specific membrane antigen) and SSTR2 (somatostatin receptor 2), respectively, on their cancer. The palpable excitement in the field stems from the finding that a proportion of patients with large metastatic burden show complete and partial responses, and this outcome is catalyzing the search for more radiotheranostics approaches. Not every patient will benefit from radiotheranostics; but, for those who cross the target-detected line, the likelihood of response is very high.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Aboagye EO, Barwick TD, Haberkorn U, et al. Radiotheranostics in oncology: Making precision medicine possible. CA Cancer J Clin. 2023. PMID: 36622841. doi:10.3322/caac.21768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。